FDA Approves American Regent’s Injectafer for Pediatric Patients
FDA approved American Regent’s Injectafer (ferric carboxymaltose injection) for the treatment of pediatric patients with iron deficiency anemia.
American Regent, a Daiichi Sankyo Group company specializing in injectables manufacturing, announced on Dec. 16, 2021, that FDA approved Injectafer for pediatric patients with iron deficiency anemia (IDA) aged one or older. This approval provides an alternative means of treatment for patients who cannot take oral iron.
Injectafer is an iron replacement product originally approved by FDA for adults in 2013. Treatment consists of a two-dose intravenous injection of 750 mg separated by at least seven days. In patients weighing less than 50 kg (110 lb), this dosage is adjusted to 15 mg/kg of body weight.
"We are pleased to build on the effective and proven treatment of Injectafer for adult IDA patients with the approval of this new pediatric use," said Linda Mundy, chief medical officer at American Regent, in a company press release. "More than 1.7 million adult patients have been treated with Injectafer in the U.S. Pediatric healthcare providers now have an option for pediatric patients as young as one year of age with IDA who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.”
Source: American Regent
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
